MYR GmbH

As more and more therapies from small- to mid-size biopharma ventures enter Western markets, Japan is taking renewed steps to attract such products to its borders by enriching funding programs to supp

New molecular entities had a rough week at the US FDA, as the agency issued a complete response letter for Gilead Sciences, Inc. ’s bulevirtide for hepatitis delta virus infection, CytoDyn, Inc. wi

Gilead Sciences, Inc. ’s drug for hospitalized COVID-19 patients did much of the work keeping the company’s revenue ship afloat as the combination of the pandemic and loss of patent protection dented

In 2020, 42 products containing a total of 41 new active substances received an EU marketing authorization, a sharp increase on the 28 NAS-containing products that were cleared in 2019, and just short